BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis. 2007;44:94-102. [PMID: 17143823 DOI: 10.1086/510080] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Khongphatthanayothin M, Avihingsanon A, Teeratakulpisarn N, Phanuphak N, Buajoom R, Suwanmala P, Phanuphak P. Feasibility and efficacy of isoniazid prophylaxis for latent tuberculosis in HIV-infected clients patients in Thailand. AIDS Res Hum Retroviruses 2012;28:270-5. [PMID: 21899431 DOI: 10.1089/aid.2011.0041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
2 Lagrange PH, Thangaraj SK, Dayal R, Deshpande A, Ganguly NK, Girardi E, Joshi B, Katoch K, Katoch VM, Kumar M, Lakshmi V, Leportier M, Longuet C, Malladi SV, Mukerjee D, Nair D, Raja A, Raman B, Rodrigues C, Sharma P, Singh A, Singh S, Sodha A, Kabeer BS, Vernet G, Goletti D. A toolbox for tuberculosis (TB) diagnosis: an Indian multicentric study (2006-2008). Evaluation of QuantiFERON-TB gold in tube for TB diagnosis. PLoS One 2013;8:e73579. [PMID: 24039990 DOI: 10.1371/journal.pone.0073579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
3 Schoeni-affolter F, Ledergerber B, Rickenbach M, Rudin C, Gunthard HF, Telenti A, Furrer H, Yerly S, Francioli P; The Swiss HIV Cohort Study. Cohort Profile: The Swiss HIV Cohort Study. International Journal of Epidemiology 2010;39:1179-89. [DOI: 10.1093/ije/dyp321] [Cited by in Crossref: 258] [Cited by in F6Publishing: 245] [Article Influence: 21.5] [Reference Citation Analysis]
4 Anandaiah A, Dheda K, Keane J, Koziel H, Moore DA, Patel NR. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011;183:987-97. [PMID: 21177884 DOI: 10.1164/rccm.201008-1246CI] [Cited by in Crossref: 22] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Powell KM, VanderEnde DS, Holland DP, Haddad MB, Yarn B, Yamin AS, Mohamed O, Sales RF, DiMiceli LE, Burns-Grant G, Reaves EJ, Gardner TJ, Ray SM. Outbreak of Drug-Resistant Mycobacterium tuberculosis Among Homeless People in Atlanta, Georgia, 2008-2015. Public Health Rep 2017;132:231-40. [PMID: 28257261 DOI: 10.1177/0033354917694008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
6 Lagrange PH, Herrmann JL. Diagnosing latent tuberculosis infection in the HIV era. Open Respir Med J 2008;2:52-9. [PMID: 19343092 DOI: 10.2174/1874306400802010052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
7 Meier NR, Battegay M, Ottenhoff THM, Furrer H, Nemeth J, Ritz N. HIV-Infected Patients Developing Tuberculosis Disease Show Early Changes in the Immune Response to Novel Mycobacterium tuberculosis Antigens. Front Immunol 2021;12:620622. [PMID: 33777000 DOI: 10.3389/fimmu.2021.620622] [Reference Citation Analysis]
8 Pullar ND, Steinum H, Bruun JN, Dyrhol-Riise AM. HIV patients with latent tuberculosis living in a low-endemic country do not develop active disease during a 2 year follow-up; a Norwegian prospective multicenter study. BMC Infect Dis 2014;14:667. [PMID: 25515915 DOI: 10.1186/s12879-014-0667-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
9 Cheng MP, Hirji A, Roth DZ, Cook VJ, Lima VD, Montaner JS, Johnston JC. Tuberculosis in HIV-infected persons in British Columbia during the HAART era. Can J Public Health 2014;105:e258-62. [PMID: 25166127 DOI: 10.17269/cjph.105.4260] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
10 Norrby M, Wannheden C, Ekström AM, Berggren I, Lindquist L. Incidence of tuberculosis and the need of prophylactic treatment in persons living with HIV in Stockholm during the era of anti-retroviral therapy 1996-2013. Infect Dis (Lond) 2018;50:807-16. [PMID: 30362392 DOI: 10.1080/23744235.2018.1486511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Souza CT, Hökerberg YH, Pacheco SJ, Rolla VC, Passos SR. Effectiveness and safety of isoniazid chemoprophylaxis for HIV-1 infected patients from Rio de Janeiro. Mem Inst Oswaldo Cruz 2009;104:462-7. [PMID: 19547873 DOI: 10.1590/s0074-02762009000300011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
12 Ramos JM, Robledano C, Masiá M, Belda S, Padilla S, Rodríguez JC, Gutierrez F. Contribution of interferon gamma release assays testing to the diagnosis of latent tuberculosis infection in HIV-infected patients: a comparison of QuantiFERON-TB Gold In Tube, T-SPOT.TB and tuberculin skin test. BMC Infect Dis 2012;12:169. [PMID: 22849726 DOI: 10.1186/1471-2334-12-169] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 3.2] [Reference Citation Analysis]
13 Hasse B, Walker AS, Fehr J, Furrer H, Hoffmann M, Battegay M, Calmy A, Fellay J, Di Benedetto C, Weber R, Ledergerber B; Swiss HIV Cohort Study. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014;58:2363-8. [PMID: 24514096 DOI: 10.1128/AAC.01868-13] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
14 Pacheco AG, Durovni B, Cavalcante SC, Lauria LM, Moore RD, Moulton LH, Chaisson RE, Golub JE. AIDS-related tuberculosis in Rio de Janeiro, Brazil. PLoS One 2008;3:e3132. [PMID: 18781195 DOI: 10.1371/journal.pone.0003132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
15 Vincenti D, Carrara S, Butera O, Bizzoni F, Casetti R, Girardi E, Goletti D. Response to region of difference 1 (RD1) epitopes in human immunodeficiency virus (HIV)-infected individuals enrolled with suspected active tuberculosis: a pilot study. Clin Exp Immunol 2007;150:91-8. [PMID: 17680823 DOI: 10.1111/j.1365-2249.2007.03462.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
16 Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, Thomsen H, Brylov A, Hetland ML, Nordgaard-lassen I, Ravn P. Prednisolone treatment affects the performance of the QuantiFERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection: . Inflammatory Bowel Diseases 2011;17:2340-9. [DOI: 10.1002/ibd.21605] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 8.6] [Reference Citation Analysis]
17 Van Rie A, Page-Shipp L, Scott L, Sanne I, Stevens W. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn 2010;10:937-46. [PMID: 20964612 DOI: 10.1586/erm.10.67] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 9.7] [Reference Citation Analysis]
18 Khawcharoenporn T, Apisarnthanarak A, Mundy LM. Assessment of risk for pulmonary tuberculosis after non-reactive tuberculin skin testing among patients with HIV infection in a resource-limited setting. Int J STD AIDS 2008;19:843-7. [DOI: 10.1258/ijsa.2008.008123] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
19 Varghese GM, Janardhanan J, Ralph R, Abraham OC. The Twin Epidemics of Tuberculosis and HIV. Curr Infect Dis Rep 2013;15:77-84. [DOI: 10.1007/s11908-012-0311-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
20 Goletti D, Navarra A, Petruccioli E, Cimaglia C, Compagno M, Cuzzi G, De Carli G, Fondaco L, Franzetti F, Giannetti A, Gori A, Lapadula G, Lichtner M, Mastroianni CM, Mazzotta V, Orchi N, Pavone P, Piacentini D, Pirriatore V, Pontali E, Sarmati L, Spolti A, Tacconelli E, Galli M, Antinori A, Calcagno A, Girardi E. Latent tuberculosis infection screening in persons newly-diagnosed with HIV infection in Italy: A multicentre study promoted by the Italian Society of Infectious and Tropical Diseases. Int J Infect Dis 2020;92:62-8. [PMID: 31887456 DOI: 10.1016/j.ijid.2019.12.031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Hoff ST, Peter JG, Theron G, Pascoe M, Tingskov PN, Aggerbeck H, Kolbus D, Ruhwald M, Andersen P, Dheda K. Sensitivity of C-Tb: a novel RD-1-specific skin test for the diagnosis of tuberculosis infection. Eur Respir J 2016;47:919-28. [PMID: 26677940 DOI: 10.1183/13993003.01464-2015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
22 van Leth F, van Crevel R, Brouwer M. Latent tuberculosis infection as a target for tuberculosis control. Future Microbiology 2015;10:905-8. [DOI: 10.2217/fmb.15.30] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
23 Chiacchio T, Petruccioli E, Vanini V, Cuzzi G, Pinnetti C, Sampaolesi A, Antinori A, Girardi E, Goletti D. Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients. Journal of Infection 2014;69:533-45. [DOI: 10.1016/j.jinf.2014.06.009] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 10.0] [Reference Citation Analysis]
24 Gutierrez EB, Gomes V, Picone CM, Suga H, Atomiya AN. Active tuberculosis and Mycobacterium tuberculosis latent infection in patients with HIV/AIDS. HIV Med 2009;10:564-72. [PMID: 19785665 DOI: 10.1111/j.1468-1293.2009.00730.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
25 Sarrazin H, Wilkinson KA, Andersson J, Rangaka MX, Radler L, van Veen K, Lange C, Wilkinson RJ. Association between Tuberculin Skin Test Reactivity, the Memory CD4 Cell Subset, and Circulating FoxP3-Expressing Cells in HIV-Infected Persons. J Infect Dis 2009;199:702-10. [DOI: 10.1086/596735] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
26 Capocci S, Smith C, Morris S, Bhagani S, Cropley I, Abubakar I, Johnson M, Lipman M. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. Eur Respir J 2015;46:165-74. [PMID: 25882810 DOI: 10.1183/09031936.00067114] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
27 del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration. Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries. Clin Infect Dis 2012;54:1364-72. [PMID: 22460971 DOI: 10.1093/cid/cis203] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
28 Gupta RK, Rice B, Brown AE, Thomas HL, Zenner D, Anderson L, Pedrazzoli D, Pozniak A, Abubakar I, Delpech V, Lipman M. Does antiretroviral therapy reduce HIV-associated tuberculosis incidence to background rates? A national observational cohort study from England, Wales, and Northern Ireland. Lancet HIV 2015;2:e243-51. [PMID: 26423197 DOI: 10.1016/S2352-3018(15)00063-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
29 Evenblij K, Verbon A, van Leth F. Intention of physicians to implement guidelines for screening and treatment of latent tuberculosis infection in HIV-infected patients in The Netherlands: a mixed-method design. BMC Public Health 2016;16:915. [PMID: 27585867 DOI: 10.1186/s12889-016-3539-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
30 Thoden J, Potthoff A, Bogner JR, Brockmeyer NH, Esser S, Grabmeier-Pfistershammer K, Haas B, Hahn K, Härter G, Hartmann M, Herzmann C, Hutterer J, Jordan AR, Lange C, Mauss S, Meyer-Olson D, Mosthaf F, Oette M, Reuter S, Rieger A, Rosenkranz T, Ruhnke M, Schaaf B, Schwarze S, Stellbrink HJ, Stocker H, Stoehr A, Stoll M, Träder C, Vogel M, Wagner D, Wyen C, Hoffmann C; Deutsche AIDS Gesellschaft., Österreichische AIDS-Gesellschaft. Therapy and prophylaxis of opportunistic infections in HIV-infected patients: a guideline by the German and Austrian AIDS societies (DAIG/ÖAG) (AWMF 055/066). Infection 2013;41 Suppl 2:S91-115. [PMID: 24037688 DOI: 10.1007/s15010-013-0504-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
31 Esmail H, Barry CE 3rd, Young DB, Wilkinson RJ. The ongoing challenge of latent tuberculosis. Philos Trans R Soc Lond B Biol Sci 2014;369:20130437. [PMID: 24821923 DOI: 10.1098/rstb.2013.0437] [Cited by in Crossref: 169] [Cited by in F6Publishing: 144] [Article Influence: 24.1] [Reference Citation Analysis]
32 Yang CH, Chan PC, Liao ST, Cheng SH, Wong WW, Huang LM, Hsueh PR, Chiou HY. Strategy to better select HIV-infected individuals for latent TB treatment in BCG-vaccinated population. PLoS One 2013;8:e73069. [PMID: 24015285 DOI: 10.1371/journal.pone.0073069] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
33 Elzi L, Steffen I, Furrer H, Fehr J, Cavassini M, Hirschel B, Hoffmann M, Bernasconi E, Bassetti S, Battegay M. Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection. BMC Infect Dis 2011;11:319. [PMID: 22085801 DOI: 10.1186/1471-2334-11-319] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
34 Kusejko K, Günthard HF, Olson GS, Zens K, Darling K, Khanna N, Furrer H, Vetter P, Bernasconi E, Vernazza P, Hoffmann M, Kouyos RD, Nemeth J; Swiss HIV Cohort Study. Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biol 2020;18:e3000963. [PMID: 33284802 DOI: 10.1371/journal.pbio.3000963] [Reference Citation Analysis]
35 Lin AW, Lau SK, Woo PC. Screening and treatment of latent tuberculosis infection among HIV-infected patients in resource-rich settings. Expert Rev Anti Infect Ther 2016;14:489-500. [PMID: 26999724 DOI: 10.1586/14787210.2016.1168693] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
36 Letang E, Ellis J, Naidoo K, Casas EC, Sánchez P, Hassan-Moosa R, Cresswell F, Miró JM, García-Basteiro AL. Tuberculosis-HIV Co-Infection: Progress and Challenges After Two Decades of Global Antiretroviral Treatment Roll-Out. Arch Bronconeumol 2020;56:446-54. [PMID: 31932150 DOI: 10.1016/j.arbres.2019.11.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
37 Fenner L, Gagneux S, Janssens JP, Fehr J, Cavassini M, Hoffmann M, Bernasconi E, Schrenzel J, Bodmer T, Böttger EC, Helbling P, Egger M; Swiss HIV Cohort and Molecular Epidemiology of Tuberculosis Study Groups. Tuberculosis in HIV-negative and HIV-infected patients in a low-incidence country: clinical characteristics and treatment outcomes. PLoS One 2012;7:e34186. [PMID: 22479556 DOI: 10.1371/journal.pone.0034186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
38 Gutsfeld C, Olaru ID, Vollrath O, Lange C. Attitudes about tuberculosis prevention in the elimination phase: a survey among physicians in Germany. PLoS One 2014;9:e112681. [PMID: 25393241 DOI: 10.1371/journal.pone.0112681] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
39 Capocci SJ, Sewell J, Smith C, Cropley I, Bhagani S, Solamalai A, Morris S, Abubakar I, Johnson MA, Lipman MCI. Cost effectiveness of testing HIV infected individuals for TB in a low TB/HIV setting. J Infect 2020;81:289-96. [PMID: 32473234 DOI: 10.1016/j.jinf.2020.05.055] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Schuetz A, Dirks J, Sester U, Haule A, Elias N, Geldmacher C, Sanga E, Maboko L, Reither K, Hoelscher M, Meyerhans A, Sester M. Pathogen prevalence may determine maintenance of antigen-specific T-cell responses in HIV-infected individuals. AIDS 2012;26:695-700. [PMID: 22301414 DOI: 10.1097/QAD.0b013e3283519a89] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
41 Mofenson LM, Laughon BE. Human Immunodeficiency Virus, Mycobacterium Tuberculosis, and Pregnancy: A Deadly Combination. Clinical Infectious Diseases 2007;45:250-3. [DOI: 10.1086/518975] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
42 Akolo C, Bada F, Okpokoro E, Nwanne O, Iziduh S, Usoroh E, Ali T, Ibeziako V, Oladimeji O, Odo M. Debunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons. World J Virol 2015;4:105-12. [PMID: 25964875 DOI: 10.5501/wjv.v4.i2.105] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
43 Davis JL, Fei M, Huang L. Respiratory infection complicating HIV infection. Curr Opin Infect Dis 2008;21:184-90. [PMID: 18317044 DOI: 10.1097/QCO.0b013e3282f54fff] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
44 Bracchi M, van Halsema C, Post F, Awosusi F, Barbour A, Bradley S, Coyne K, Dixon-Williams E, Freedman A, Jelliman P, Khoo S, Leen C, Lipman M, Lucas S, Miller R, Seden K, Pozniak A. British HIV Association guidelines for the management of tuberculosis in adults living with HIV 2019. HIV Med 2019;20 Suppl 6:s2-s83. [PMID: 31152481 DOI: 10.1111/hiv.12748] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Diaz A, Diez M, Bleda MJ, Aldamiz M, Camafort M, Camino X, Cepeda C, Costa A, Ferrero O, Geijo P, Iribarren JA, Moreno S, Moreno ME, Labarga P, Pinilla J, Portu J, Pulido F, Rosa C, Santamaría JM, Telenti M, Trapiella L, Trastoy M, Viciana P. Eligibility for and outcome of treatment of latent tuberculosis infection in a cohort of HIV-infected people in Spain. BMC Infect Dis 2010;10:267. [PMID: 20840743 DOI: 10.1186/1471-2334-10-267] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
46 Salgame P, Geadas C, Collins L, Jones-López E, Ellner JJ. Latent tuberculosis infection--Revisiting and revising concepts. Tuberculosis (Edinb) 2015;95:373-84. [PMID: 26038289 DOI: 10.1016/j.tube.2015.04.003] [Cited by in Crossref: 74] [Cited by in F6Publishing: 64] [Article Influence: 12.3] [Reference Citation Analysis]
47 Lange C, van Leth F, Sester M; TBnet. Viral Load and Risk of Tuberculosis in HIV Infection. J Acquir Immune Defic Syndr 2016;71:e51-3. [PMID: 26761521 DOI: 10.1097/QAI.0000000000000834] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
48 Dobler CC, Bosnic-Anticevich S, Armour CL. Physicians' perspectives on communication and decision making in clinical encounters for treatment of latent tuberculosis infection. ERJ Open Res 2018;4:00146-2017. [PMID: 29577042 DOI: 10.1183/23120541.00146-2017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
49 Sester M, van Leth F, Bruchfeld J, Bumbacea D, Cirillo DM, Dilektasli AG, Domínguez J, Duarte R, Ernst M, Eyuboglu FO, Gerogianni I, Girardi E, Goletti D, Janssens J, Julander I, Lange B, Latorre I, Losi M, Markova R, Matteelli A, Milburn H, Ravn P, Scholman T, Soccal PM, Straub M, Wagner D, Wolf T, Yalcin A, Lange C. Risk Assessment of Tuberculosis in Immunocompromised Patients. A TBNET Study. Am J Respir Crit Care Med 2014;190:1168-76. [DOI: 10.1164/rccm.201405-0967oc] [Cited by in Crossref: 138] [Cited by in F6Publishing: 59] [Article Influence: 19.7] [Reference Citation Analysis]
50 Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD; North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of the International Epidemiologic Databases to Evaluate AIDS (IeDEA). Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis 2011;204:893-901. [PMID: 21849286 DOI: 10.1093/infdis/jir421] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
51 Pozniak AL, Coyne KM, Miller RF, Lipman MC, Freedman AR, Ormerod LP, Johnson MA, Collins S, Lucas SB; BHIVA Guidelines Subcommittee. British HIV Association guidelines for the treatment of TB/HIV coinfection 2011. HIV Med 2011;12:517-24. [PMID: 21951595 DOI: 10.1111/j.1468-1293.2011.00954.x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
52 Gerin M, Bourgarit A. [Interferon gamma release assay tests and HIV infection]. Rev Mal Respir 2018;35:883-6. [PMID: 30224209 DOI: 10.1016/j.rmr.2018.08.013] [Reference Citation Analysis]
53 Thacher EG, Cavassini M, Audran R, Thierry AC, Bollaerts A, Cohen J, Demoitié MA, Ejigu D, Mettens P, Moris P, Ofori-Anyinam O, Spertini F. Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial. AIDS 2014;28:1769-81. [PMID: 24911353 DOI: 10.1097/QAD.0000000000000343] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 5.2] [Reference Citation Analysis]
54 Taarnhøj GA, Engsig FN, Ravn P, Johansen IS, Larsen CS, Røge B, Andersen AB, Obel N. Incidence, risk factors and mortality of tuberculosis in Danish HIV patients 1995-2007. BMC Pulm Med 2011;11:26. [PMID: 21605366 DOI: 10.1186/1471-2466-11-26] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
55 Lee SS, Lin HH, Tsai HC, Su IJ, Yang CH, Sun HY, Hung CC, Sy CL, Wu KS, Chen JK, Chen YS, Fang CT. A Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort Study. PLoS One 2015;10:e0135801. [PMID: 26280669 DOI: 10.1371/journal.pone.0135801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
56 Cheallaigh CN, Fitzgerald I, Grace J, Singh GJ, El-Eraki N, Gibbons N, Keane J, Rogers TR, Clarke S, Bergin C. Interferon gamma release assays for the diagnosis of latent TB infection in HIV-infected individuals in a low TB burden country. PLoS One 2013;8:e53330. [PMID: 23382842 DOI: 10.1371/journal.pone.0053330] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
57 Fenner L, Gagneux S, Helbling P, Battegay M, Rieder HL, Pfyffer GE, Zwahlen M, Furrer H, Siegrist HH, Fehr J, Dolina M, Calmy A, Stucki D, Jaton K, Janssens JP, Stalder JM, Bodmer T, Ninet B, Böttger EC, Egger M; Swiss HIV Cohort Study Group., Molecular Epidemiology of Tuberculosis Study Group. Mycobacterium tuberculosis transmission in a country with low tuberculosis incidence: role of immigration and HIV infection. J Clin Microbiol 2012;50:388-95. [PMID: 22116153 DOI: 10.1128/JCM.05392-11] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
58 Janbaz KH, Qadir MI, Ahmad B, Sarwar A, Yaqoob N, Masood MI. Tuberculosis – burning issues: Multidrug resistance and HIV-coinfection. Critical Reviews in Microbiology 2012;38:267-75. [DOI: 10.3109/1040841x.2012.664539] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Batista Jd, de Albuquerque Mde F, Maruza M, Ximenes RA, Santos ML, Montarroyos UR, de Barros Miranda-Filho D, Lacerda HR, Rodrigues LC. Incidence and risk factors for tuberculosis in people living with HIV: cohort from HIV referral health centers in Recife, Brazil. PLoS One 2013;8:e63916. [PMID: 23675515 DOI: 10.1371/journal.pone.0063916] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
60 Karo B, Haas W, Kollan C, Gunsenheimer-Bartmeyer B, Hamouda O, Fiebig L; German ClinSurv HIV Study Group. Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors. BMC Infect Dis 2014;14:148. [PMID: 24646042 DOI: 10.1186/1471-2334-14-148] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
61 Rieder HL. Editorial Commentary: Preventing Latent Tuberculosis among HIV‐Infected Patients: Efficacious and Effective, yet Inefficient? CLIN INFECT DIS 2007;44:103-4. [DOI: 10.1086/510093] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
62 Hamlyn E, Childs K, Post FA. Reducing Tuberculosis Incidence in HIV-Infected Patients by Tuberculin Skin Testing, Preventive Treatment, and Antiretroviral Therapy. Clinical Infectious Diseases 2007;44:1393-4. [DOI: 10.1086/516608] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
63 Stephan C, Wolf T, Goetsch U, Bellinger O, Nisius G, Oremek G, Rakus Z, Gottschalk R, Stark S, Brodt H, Staszewski S. Comparing QuantiFERON-tuberculosis gold, T-SPOT tuberculosis and tuberculin skin test in HIV-infected individuals from a low prevalence tuberculosis country. AIDS 2008;22:2471-9. [DOI: 10.1097/qad.0b013e3283188415] [Cited by in Crossref: 70] [Cited by in F6Publishing: 20] [Article Influence: 5.4] [Reference Citation Analysis]
64 van der Werf MJ, Ködmön C, Zucs P, Hollo V, Amato-Gauci AJ, Pharris A. Tuberculosis and HIV coinfection in Europe: looking at one reality from two angles. AIDS 2016;30:2845-53. [PMID: 27755106 DOI: 10.1097/QAD.0000000000001252] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 4.3] [Reference Citation Analysis]
65 Holmberg V, Soini H, Kivelä P, Ollgren J, Ristola M. Epidemiology and outcome of HIV patients in Finland co-infected with tuberculosis 1998-2015. BMC Infect Dis 2019;19:264. [PMID: 30885144 DOI: 10.1186/s12879-019-3890-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
66 Balcells ME, Pérez CM, Chanqueo L, Lasso M, Villanueva M, Espinoza M, Villarroel L, García P. A comparative study of two different methods for the detection of latent tuberculosis in HIV-positive individuals in Chile. International Journal of Infectious Diseases 2008;12:645-52. [DOI: 10.1016/j.ijid.2008.03.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 37] [Article Influence: 3.0] [Reference Citation Analysis]
67 Haraka F, Glass TR, Sikalengo G, Gamell A, Ntamatungiro A, Hatz C, Tanner M, Furrer H, Battegay M, Letang E. A Bundle of Services Increased Ascertainment of Tuberculosis among HIV-Infected Individuals Enrolled in a HIV Cohort in Rural Sub-Saharan Africa. PLoS One 2015;10:e0123275. [PMID: 25897491 DOI: 10.1371/journal.pone.0123275] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
68 Golub JE, Astemborski J, Ahmed M, Cronin W, Mehta SH, Kirk GD, Vlahov D, Chaisson RE. Long-term effectiveness of diagnosing and treating latent tuberculosis infection in a cohort of HIV-infected and at-risk injection drug users. J Acquir Immune Defic Syndr 2008;49:532-7. [PMID: 18989223 DOI: 10.1097/QAI.0b013e31818d5c1c] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
69 Miró JM. Prevención de las infecciones oportunistas en pacientes adultos y adolescentes infectados por el VIH en el año 2008. Enfermedades Infecciosas y Microbiología Clínica 2008;26:437-64. [DOI: 10.1157/13125642] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]